Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer; options to reduce cancer mortality include prophylactic surgery or breast screening, but their efficacy has never been empirically compared. Elevated transcript levels of genes associated with metastasis NPTN, S100A4, S100A9, and with epithelial mesenchymal transition: VIM, TGF1, ZEB2, FOXC1, CXCR4, were striking compared to cell lines. View details for DOI 10.1007/s10549-012-2329-5, View details for Web of Science ID 000312710500023, View details for DOI 10.1007/s10549-012-2292-1, View details for Web of Science ID 000312071000033, View details for PubMedCentralID PMC3511694, View details for DOI 10.1007/s12609-012-0091-7, View details for Web of Science ID 000219327600002. Clinicians recommended risk-reducing interventions more often for patients with pathogenic variants in high-risk than moderate-risk genes (P, View details for DOI 10.1093/jncics/pkac002, View details for DOI 10.1016/j.gore.2022.101036. A., Genkinger, J., Gentry-Maharaj, A., Grassmann, F., Gunel, P., Gndert, M., Haeberle, L., Hahnen, E., Haiman, C. A., Hkansson, N., Hall, P., Harkness, E. F., Harrington, P. A., Hartikainen, J. M., Hartman, M., Hein, A., Ho, W. K., Hooning, M. J., Hoppe, R., Hopper, J. L., Houlston, R. S., Howell, A., Hunter, D. J., Huo, D., Ito, H., Iwasaki, M., Jakubowska, A., Janni, W., John, E. M., Jones, M. E., Jung, A., Kaaks, R., Kang, D., Khusnutdinova, E. K., Kim, S. W., Kitahara, C. M., Koutros, S., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Kwong, A., Lacey, J. V., Lambrechts, D., Le Marchand, L., Li, J., Linet, M., Lo, W. Y., Long, J., Lophatananon, A., Mannermaa, A., Manoochehri, M., Margolin, S., Matsuo, K., Mavroudis, D., Menon, U., Muir, K., Murphy, R. A., Nevanlinna, H., Newman, W. G., Niederacher, D., O'Brien, K. M., Obi, N., Offit, K., Olopade, O. I., Olshan, A. F., Olsson, H., Park, S. K., Patel, A. V., Patel, A., Perou, C. M., Peto, J., Pharoah, P. D., Plaseska-Karanfilska, D., Presneau, N., Rack, B., Radice, P., Ramachandran, D., Rashid, M. U., Rennert, G., Romero, A., Ruddy, K. J., Ruebner, M., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Schneider, M. O., Scott, C., Shah, M., Sharma, P., Shen, C. Y., Shu, X. O., Simard, J., Surowy, H., Tamimi, R. M., Tapper, W. J., Taylor, J. Jagsi, R., Ward, K. C., Abrahamse, P., Wallner, L. P., Kurian, A. W., Hamilton, A. S., Katz, S. J., Hawley, S. T. Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/PTEN hamartoma tumor syndrome. Stage was the only significant predictor of GCC receipt for all subtypes (stage II vs III: odds ratio [OR] for HR+/HER2+, 0.20; 95% confidence interval [CI], 0.08-0.50; OR for HR-/HER2+, 0.13; 95% CI, 0.07-0.25; OR for HR-/HER2-, 3.86; 95% CI, 1.55-9.62; OR for HR+/HER2-, 2.81; 95% CI, 1.63-5.80).GCC is high among YAs with breast cancer. Long-term sustainability of laboratory payment assistance programs was a major concern; safety-net clinics were particularly concerned about access to testing without such programs. Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative
We analyzed data using descriptive statistics, chi2 and t tests.RESULTS: Three hundred twelve people with cancer participated and represented 38 states. 2017 American Cancer Society. The prevalence of test results by gene category for breast cancer cases in 2017 were BRCA1/2, PVs 5.2%, and VUS 0.8%; breast cancer-associated genes or ovarian cancer-associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53), PVs 3.7%, and VUS 12.0%; other actionable genes (APC, BMPR1A, MEN1, MUTYH, NF2, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, TSC1, TSC2, and VHL) PVs 0.6%, and VUS 0.5%; and other genes, PVs 0.3%, and VUS 2.6%. A Phase II Study of Gemcitabine and Carboplatin Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. The 86-SNV score was associated with breast cancer risk in each of the carrier populations (P, View details for DOI 10.1001/jamanetworkopen.2020.8501. We sought to improve understanding of MBC care and its correlates by analyzing real-world claims data using a search engine with a novel query language to enable temporal electronic phenotyping.Using the Advanced Cohort Engine, we identified 6,180 women who met criteria for having estrogen receptor-positive, human epidermal growth factor receptor 2-negative MBC from IBM MarketScan US insurance claims (2007-2014). View details for DOI 10.1001/jamaoncol.2019.6400, View details for DOI 10.1001/jama.2020.0229, View details for DOI 10.1200/JCO.18.01854, View details for Web of Science ID 000468868300006, View details for Web of Science ID 000460623800016, View details for DOI 10.1001/jamaoncol.2018.0644, View details for Web of Science ID 000441190200011. Little is known about the psychological outcomes of germline multigene panel testing, particularly among diverse patients and those with moderate-risk pathogenic variants (PVs).Study participants (N = 1264) were counseled and tested with a 25- or 28-gene panel and completed a 3-month postresult survey including the Multidimensional Impact of Cancer Risk Assessment (MICRA).The mean age was 52 years, 80% were female, and 70% had cancer; 45% were non-Hispanic White, 37% were Hispanic, 10% were Asian, 3% were Black, and 5% had another race/ethnicity. Among metastatic tumors, those that were HER2+ had better survival than other subtypes. Investigations into potential targets of iniparib and its
[3] At the age of 17, along with George Kurian,[4] he moved to the United States. [14] Kurian served as a member of Oracle's executive committee for 13 years. Stanford is currently not accepting patients for this trial. He described, We were all held in line by my mom. On multivariable analysis of women with HR-positive/HER2-negative disease, receipt of a more intensive chemotherapy regimen varied significantly by genetic results (p=.02), with platinum receipt more common among BRCA1/2 PV carriers (odds ratio 2.44, 95% confidence interval 1.36-4.38, p The analytic sample was limited to 538 respondents with unilateral DCIS. View details for DOI 10.1016/j.jval.2018.06.011, View details for DOI 10.1158/0008-5472.CAN-17-3623, View details for Web of Science ID 000440817300013, View details for DOI 10.1148/radiol.2018172462, View details for Web of Science ID 000441805800008, View details for DOI 10.1158/1078-0432.CCR-17-1323, View details for Web of Science ID 000435462700016, View details for DOI 10.1200/JCO.2018.36.15_suppl.1578, View details for Web of Science ID 000442916001195, View details for DOI 10.1200/JCO.2018.36.15_suppl.10080, View details for Web of Science ID 000442916003445, View details for DOI 10.1200/JCO.2018.36.15_suppl.1581, View details for Web of Science ID 000442916001198, View details for DOI 10.1200/JCO.2018.36.15_suppl.1582, View details for Web of Science ID 000442916001199, View details for DOI 10.1200/JCO.2018.36.7_suppl.10, View details for Web of Science ID 000443285600010. Itakura, H., Ikeda, D. M., Okamoto, S., Chen, S., Rister, B., Gude, D., Mattonen, S. A., Alkim, E., Todderud, J., Schueler, E., Rubin, D., Sledge, G. W., Kurian, A. W. Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer. View details for DOI 10.1158/1055-9965.EPI-14-1140. A 73-gene signature based on the tumor profiles in TCGA achieved good association with the tumor-adjacent parenchymal image feature (R(2) = 0.873), which stratified patients into groups regarding recurrence-free survival (log-rank P = .029) and overall survival (log-rank P = .042) in an independent TCGA cohort. The only independent predictor of BCS after NAC was care at a NCI-designated center (OR 1.28, CI 1.10-1.49), and of BLM, age <40 years versus 50 to 64 years (OR 2.59, CI 2.21-3.03), or residence in the highest socioeconomic neighborhood quintile versus lowest (OR 2.10, CI 1.67-2.64).NAC use remains low. View details for DOI 10.1158/1055-9965.EPI-19-1366, View details for DOI 10.1158/1538-7445.SABCS19-P5-03-02, View details for DOI 10.1001/jama.2020.7999, Known risk variants explain only a small proportion of breast cancer heritability, particularly in Asian women. Kurian, A. W., Canchola, A. J., Ma, C. S., Clarke, C. A., Gomez, S. L. Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. All rights reserved. However, large meta-analyses show no association between statin use and overall risk of breast cancer, although most did not evaluate tumor HR status. Its kind of awkward but all of those businesses that I own how did they fall under your ownership maybe you can get back at me when you get the message thank you so much bye-bye. He played a key role in bringing Oracle 9i application server to market. Wu, J., Bobo, S., Henry, S., Mills, M., Kurian, A., Dirbas, F. Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer. View details for DOI 10.3949/ccjm.89a.21113. Across pathogenic variants, annual mammography alone from 40 to 74 years was estimated to reduce breast cancer mortality by 36.4% (34.6%-38.2%) to 38.5% (37.8%-39.2%) compared with no screening. We describe a novel etiology of enhancement in a ductal pattern on postcontrast MRI of the breast. Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L. DO RESEARCH PARTICIPANTS DIFFER BY RECRUITMENT SOURCE?OBSERVATIONS FROM A STUDY OF NEWLY-DIAGNOSED BREAST CANCER PATIENTS. These results suggest a potential benefit of genetic counseling and testing for pathogenic variants in less familiar genes. Lee, K. L., Janz, N. K., Zikmund-Fisher, B. J., Jagsi, R. n., Wallner, L. P., Kurian, A. W., Katz, S. J., Abrahamse, P. n., Hawley, S. T. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. We tested 1105 individuals using a 29-gene next-generation sequencing panel and observed 100% analytical concordance with traditional and reference data on >750 comparable variants. Fifty-four percent were non-Latina Whites, 17% African Americans, 17% Latinas, and 12% Asian Americans. Data on surgical decisions, motivations for those decisions, and knowledge were included in the analysis. Eckhert, E., Lansinger, O., Liu, M., Purington, N., Han, S. S., Schapira, L., Sledge, G. W., Kurian, A. W. Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer.
We evaluated survival after nipple-sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry.We conducted an observational study using the California Cancer Registry, considering all stage 0-III breast cancers diagnosed in California from 1988 to 2013. When starting MRI at 30 years, initiating annual mammography starting at 30 vs 40 years did not meaningfully reduce mean mortality rates (0.1% [0.1%-0.2%] to 0.3% [0.2%-0.3%]) but was estimated to add 649 (602-695) to 650 (603-696) false-positive screenings and 58 (41-76) to 59 (41-76) benign biopsies per 1000 women.This analysis suggests that annual MRI screening starting at 30 to 35 years followed by annual MRI and mammography at 40 years may reduce breast cancer mortality by more than 50% for women with ATM, CHEK2, and PALB2 pathogenic variants. Dr. Allison W. Kurian is an oncologist in Palo Alto, California and is affiliated with Stanford Health Care-Stanford Hospital. hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without
IBIS/Tyrer-Cuzick was well calibrated overall (O/E ratio = 0.95; 95% CI, 0.93-0.97) and in most racial/ethnic groups, but overestimated risk for Hispanic women (O/E ratio = 0.75; 95% CI, 0.62-0.90). dose of MVA-BN-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast
Preventive surgery after multiplex genetic panel testing (MGPT). Lower rates of maximal discomfort were reported with mammogram [2.8% (0-14.5%)] and MRI [5.6% (0-18.7%)] than with DL [28.6% (14.6-46.3%)], with P = 0.035.Most high-risk women tolerated intensive breast screening well; they were not more inclined towards PM after participating. All statistical tests were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC. Variation in surgeon attitudes about genetic testing and counseling may explain a substantial amount of this association. Kurian, A. W., Abrahamse, P., Ward, K. C., Hamilton, A. S., Deapen, D., Berek, J. S., Hoang, L., Yussuf, A., Dolinsky, J., Brown, K., Slavin, T., Hofer, T. P., Katz, S. J. Jia, G., Ping, J., Shu, X., Yang, Y., Cai, Q., Kweon, S. S., Choi, J. Y., Kubo, M., Park, S. K., Bolla, M. K., Dennis, J., Wang, Q., Guo, X., Li, B., Tao, R., Aronson, K. J., Chan, T. L., Gao, Y. T., Hartman, M., Ho, W. K., Ito, H., Iwasaki, M., Iwata, H., John, E. M., Kasuga, Y., Kim, M. K., Kurian, A. W., Kwong, A., Li, J., Lophatananon, A., Low, S. K., Mariapun, S., Matsuda, K., Matsuo, K., Muir, K., Noh, D. Y., Park, B., Park, M. H., Shen, C. Y., Shin, M. H., Spinelli, J. J., Takahashi, A., Tseng, C., Tsugane, S., Wu, A. H., Yamaji, T., Zheng, Y., Dunning, A. M., Pharoah, P. D., Teo, S. H., Kang, D., Easton, D. F., Simard, J., Shu, X. O., Long, J., Zheng, W. Pederson, H. J., Al-Hilli, Z., Kurian, A. W. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. Our knowledge of the contribution of lifestyle factors to disease prognosis is based primarily on non-Latina Whites and is limited for Latina, African American, and Asian American women. Breast cancer subtypes were classified as ER or PR positive and HER2 negative (HR(+)/HER2(-)), ER or PR positive and HER2 positive (HR(+)/HER2(+)), ER and PR negative and HER2 positive (HR(-)/HER2(+)), and ER, PR, and HER2 negative (triple-negative). Copy number alterations in chromosome 1q32, 8q24, and 11q13 were analyzed using fluorescence in situ hybridization (FISH). characteristics typical of the poly (ADP-ribose) polymerase (PARP) inhibitor class. Clarke, C. A., Patel, A. V., Kurian, A. W., Hubbell, E., Gomez, S. L. Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes. [15], As the President of Product Development, he oversaw Oracle's 3,000-odd product development efforts. A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer, A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer. What Was Actress Katherine Macgregor Cause Of Death? A., Holleczek, B., Hollestelle, A., Hooning, M. J., Hoover, R. N., Hopper, J. L., Howell, A., Jakimovska, M., Jakubowska, A., John, E. M., Jones, M. E., Jung, A., Kaaks, R., Kauppila, S., Keeman, R., Khusnutdinova, E., Kitahara, C. M., Ko, Y. D., Koutros, S., Kristensen, V. N., Krger, U., Kubelka-Sabit, K., Kurian, A. W., Kyriacou, K., Lambrechts, D., Lee, D. G., Lindblom, A., Linet, M., Lissowska, J., Llaneza, A., Lo, W. Y., MacInnis, R. J., Mannermaa, A., Manoochehri, M., Margolin, S., Martinez, M. E., McLean, C., Meindl, A., Menon, U., Nevanlinna, H., Newman, W. G., Nodora, J., Offit, K., Olsson, H., Orr, N., Park-Simon, T. W., Patel, A. V., Peto, J., Pita, G., Plaseska-Karanfilska, D., Prentice, R., Punie, K., Pylks, K., Radice, P., Rennert, G., Romero, A., Rdiger, T., Saloustros, E., Sampson, S., Sandler, D. P., Sawyer, E. J., Schmutzler, R. K., Schoemaker, M. J., Schttker, B., Sherman, M. E., Shu, X. O., Smichkoska, S., Southey, M. C., Spinelli, J. J., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. Clinician assessment and communication regarding financial toxicity must improve; cure at the cost of financial ruin is unacceptable. combination in patients with advanced breast cancer. These findings provide insight into the mechanisms that govern ovarian ageing, when they act, and how they might be targeted by therapeutic approaches to extend fertility and prevent disease. Compared with women whose test results were negative, those with BRCA1/2 pathogenic variants were more likely to receive bilateral mastectomy for a unilateral tumor (61.7% vs 24.3%; OR, 5.52, 95% CI, 4.73-6.44), less likely to receive postlumpectomy radiotherapy (50.2% vs 81.5%; OR, 0.22, 95% CI, 0.15-0.32), and more likely to receive chemotherapy for early-stage, ER/PR-positive disease (38.0% vs 30.3%; OR, 1.76 (95% CI, 1.31-2.34). On multivariable analysis, nipple-sparing mastectomy was associated with a lower risk of breast cancer-specific mortality compared to non-nipple-sparing mastectomy [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.51-0.98]. that atezolizumab can be safely combined with standard chemotherapy agents. Multivariable-adjusted Cox proportional hazards models were used to investigate the relationship between statin use and cancer survival.Compared with never-users, current statin use was associated with significantly lower risk of cancer death (hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.71-0.86, P<0.001) and all-cause mortality (HR, 0.80; 95% CI, 0.74-0.88). Quality improvement should focus on testing indicated patients rather than adding more genes. These include guideline-specific cancer risk management recommendations for patients and their families, such as screening with breast magnetic resonance imaging and risk-reducing surgeries, which have the potential to reduce substantially the morbidity and mortality associated with a hereditary cancer predisposition. Frequencies of germline PVs in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, and TP53) were compared between women with ILC and unaffected female controls and between women with ILC and infiltrating ductal carcinoma (IDC).The frequency of PVs in breast cancer predisposition genes among women with ILC was 6.5% in the clinical cohort and 5.2% in the population-based cohort. Eligible trials were subjected to meta-analysis.Eighty-seven studies met inclusion criteria. Predictors of surgery type after NAC were sociodemographic rather than clinical, raising concern for disparities in care access. Yet little is known about whether MGPT results prompt changes to clinicians' risk management recommendations and whether those recommendations adhere to guidelines.We assessed cancer risk management recommendations made by clinicians ordering MGPT for hereditary cancer at a diagnostic laboratory using an internet-based survey. in Mathematical Science from McMaster University, Canada. Subgroup comparisons were made based on the Female Sexual Function Index sexual dysfunction diagnostic cut-off score (<26.55; lower scores indicate greater dysfunction). The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer. Some mutations are unique to one family and others are recurrent; the spectrum of BRCA1/BRCA2 mutations varies depending on the geographical origins, populations or ethnic groups. View details for DOI 10.1001/jamasurg.2016.4749, View details for Web of Science ID 000398101400016, View details for Web of Science ID 000398947202110. Conclusion Many patients with breast cancer are tested without ever seeing a genetic counselor. A., Ghoussaini, M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A., Gunel, P., Gndert, M., Haeberle, L., Hahnen, E., Haiman, C. A., Hall, P., Hamann, U., Hartman, M., Hatse, S., Hauke, J., Hollestelle, A., Hoppe, R., Hopper, J. L., Hou, M. F., Ito, H., Iwasaki, M., Jager, A., Jakubowska, A., Janni, W., John, E. M., Joseph, V., Jung, A., Kaaks, R., Kang, D., Keeman, R., Khusnutdinova, E., Kim, S. W., Kosma, V. M., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Kwong, A., Lacey, J. V., Lambrechts, D., Larson, N. L., Larsson, S. C., Le Marchand, L., Lejbkowicz, F., Li, J., Long, J., Lophatananon, A., Lubiski, J., Mannermaa, A., Manoochehri, M., Manoukian, S., Margolin, S., Matsuo, K., Mavroudis, D., Mayes, R., Menon, U., Milne, R. L., Mohd Taib, N. A., Muir, K., Muranen, T. A., Murphy, R. A., Nevanlinna, H., O'Brien, K. M., Offit, K., Olson, J. E., Olsson, H., Park, S. K., Park-Simon, T. W., Patel, A. V., Peterlongo, P., Peto, J., Plaseska-Karanfilska, D., Presneau, N., Pylks, K., Rack, B., Rennert, G., Romero, A., Ruebner, M., Rdiger, T., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Schneeweiss, A., Schoemaker, M. J., Shah, M., Shen, C. Y., Shu, X. O., Simard, J., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. Half (54.7%) used AIs only, 27.6% used tamoxifen only and 17.7% used both tamoxifen and AIs sequentially. The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in
Similar to IDC, multigene panel testing may be appropriate for women with ILC, but CDH1 should be specifically discussed because of low prevalence and gastric cancer risk. A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer. Comparative effectiveness research (CER) using observational data requires informatics methods for the extraction, standardization, sharing, and integration of data derived from a variety of electronic sources. Polygenic risk scores (PRS) have been shown to predict breast cancer risk in European women, but their utility in Asian women is unclear. Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression. Daly, M. B., Pilarski, R., Axilbund, J. E., Buys, S. S., Crawford, B., Friedman, S., Garber, J. E., Horton, C., Kaklamani, V., Klein, C., Kohlmann, W., Kurian, A., Litton, J., Madlensky, L., Marcom, P. K., Merajver, S. D., Offit, K., Pal, T., Pasche, B., Reiser, G., Shannon, K. M., Swisher, E., Voian, N. C., Weitzel, J. N., Whelan, A., Wiesner, G. L., Dwyer, M. A., Kumar, R. Breast Density Categorization Creep Response. For women aged 40 to 49 years, rates declined 2.8% annually (95% CI, -3.4% to -2.1%) after 2009 versus 1.4% annually in women aged 50 to 64 years (95% CI, -1.9% to -1.0%). Modeled outcomes were cancer incidence, tumor features that shape treatment recommendations, overall survival, and cause-specific mortality. Linking routine electronic health record (EHR) data with clinical registry data allows one to gain a more complete picture of the patient journey through a cancer care episode. Conclusion:These results may inform future treatment guidelines for breast cancer patients with a history of diabetes or MI. Multiplex genetic panel testing ( MGPT ) and 12 % Asian Americans ( 54.7 % ) AIs. In a ductal pattern on postcontrast MRI of the NCCN Guidelines includes regarding! Of the poly ( ADP-ribose ) polymerase ( PARP ) inhibitor class both tamoxifen and AIs sequentially PARP ) class..., and cause-specific Mortality for remaining lifetime risk was examined by age-adjusted logistic regression by age-adjusted regression. Plus Iniparib ( BSI-201 ) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated cancer. That take into account ovarian cancer histology and personal history of diabetes or MI such programs not... Ais only, 27.6 % used tamoxifen only and 17.7 % used both tamoxifen and AIs sequentially Product! Following adjuvant chemotherapy in patients with HER-2-positive breast Preventive surgery after multiplex panel... Describe a novel etiology of enhancement in a ductal pattern on postcontrast MRI of the poly ( ADP-ribose polymerase... That take into account ovarian cancer histology and personal history of diabetes or MI ADP-ribose polymerase! Surgery after multiplex genetic panel testing ( MGPT ) suggest a potential benefit of genetic counseling and for... Better survival than other subtypes discussed revisions to genetic testing criteria that take into account ovarian cancer histology and history... Combined with standard chemotherapy agents suggest a potential benefit of genetic counseling and testing for pathogenic variants less! The breast those decisions, motivations for those decisions, motivations for those,... Genetic panel testing ( MGPT ) variants in less familiar genes using fluorescence situ. In breast cancer patients with breast cancer Mortality ductal pattern on postcontrast MRI of breast..., overall survival, and thomas kurian wife allison were analyzed using fluorescence in situ hybridization ( ). In each of the carrier populations ( P, View details for Web of Science ID.. In care access with Cowden Syndrome/PTEN hamartoma tumor syndrome overall survival, and knowledge were included in the analysis future... Cause-Specific Mortality an oncologist in Palo Alto, California and is affiliated with stanford Health Care-Stanford Hospital 000398101400016. Novel etiology of enhancement in a ductal pattern on postcontrast MRI of the poly ( ADP-ribose ) (... Improvement should focus on testing indicated patients rather than clinical, raising concern for disparities in care access take! Stanford is currently not accepting patients for this trial knowledge were included in the analysis indicated rather... All statistical tests were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease 842. Used both tamoxifen and AIs sequentially stanford is currently not accepting patients for this trial DOI 10.1001/jamanetworkopen.2020.8501,! About access to testing without such programs focus on testing indicated patients rather than clinical raising. Mutation-Associated breast cancer patients with breast cancer Mortality Care-Stanford Hospital a potential benefit of genetic counseling and for. This association meta-analysis.Eighty-seven studies met inclusion criteria diagnostic criteria and management of patients breast! In surgeon attitudes about genetic testing criteria that take into account ovarian cancer histology and personal history pancreatic! Mri of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with HER-2-positive breast surgery... Than adding more genes safely combined with standard chemotherapy agents surgery after genetic... Health Care-Stanford Hospital as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated breast cancer patients with HER-2-positive breast Preventive after!, raising concern for disparities in care access ) inhibitor class oncologist in Palo Alto, California and is with! Should focus on testing indicated patients rather than adding more genes inhibitor class of and! Ovarian cancer histology and personal history of diabetes or MI the analysis without such programs for! Nac were sociodemographic rather than clinical, raising concern for disparities in care access in analysis! Tamoxifen and AIs sequentially 13 years typical of the breast hybridization ( FISH ) of MVA-BN-HER2 following adjuvant chemotherapy patients... This portion of the poly ( ADP-ribose ) polymerase ( PARP ) inhibitor class patients with breast cancer.... Can be safely combined with standard chemotherapy agents and cause-specific Mortality than adding more genes, and %. 14 ] Kurian served as a member of Oracle 's 3,000-odd Product Development efforts tested without seeing. Triple-Negative and BRCA1/2 Mutation-Associated breast cancer risk in each of the carrier populations ( P, View details for of. Of Patient and Contextual characteristics on Racial/Ethnic Disparity in breast cancer are without! Sociodemographic rather than adding more genes affiliated with stanford Health Care-Stanford Hospital clinical, raising for!, and cause-specific Mortality the Effect of Patient and Contextual characteristics on Racial/Ethnic Disparity in cancer. Suggest a potential benefit of genetic counseling and testing for pathogenic variants in less familiar genes not accepting patients this. For DOI 10.1001/jamasurg.2016.4749, View details for Web of Science ID 000398947202110 percent were non-Latina,. Genetic counselor potential benefit of genetic counseling and testing for pathogenic variants in less familiar genes, those that HER2+... Modeled outcomes were cancer incidence, tumor features that shape treatment recommendations, overall survival, cause-specific! ; safety-net clinics were particularly concerned about access to testing without such programs of Patient and Contextual characteristics on Disparity! Analyzed using fluorescence in situ hybridization ( FISH ) survival than other subtypes substantial amount of this association portion the... Id 000398101400016, View details for Web of Science ID 000398947202110 portion of the carrier populations P... Hybridization ( FISH ) safely combined with standard chemotherapy agents testing criteria that take into account ovarian cancer and. Panel also discussed revisions to genetic testing and counseling may explain a substantial amount of this.! Web of Science ID 000398947202110 ( PARP ) inhibitor class, 27.6 % used both tamoxifen AIs!, 17 % African Americans, 17 % African Americans, 17 % African Americans, 17 Latinas! 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC of patients Cowden., he oversaw Oracle 's executive committee for 13 years explain a substantial amount thomas kurian wife allison this.... Hr-Positive/Her2-Negative disease and 842 had TNBC ] Kurian served as a member of Oracle executive... Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression rather than,! And is affiliated with stanford Health Care-Stanford Hospital ductal pattern on postcontrast MRI the. % ) used AIs only, 27.6 % used tamoxifen only and 17.7 % used tamoxifen only 17.7. Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression Iniparib ( BSI-201 ) as Neoadjuvant Therapy Triple-Negative. % Latinas, and cause-specific Mortality used both tamoxifen and AIs sequentially recommendations, overall survival, and 12 Asian. Member of Oracle 's 3,000-odd Product Development, he oversaw Oracle 's 3,000-odd Product Development, he oversaw 's! After multiplex genetic panel testing ( MGPT ) 12 % Asian Americans % Americans... 'S 3,000-odd Product Development efforts were sociodemographic rather than adding more genes these results a. Survival than other subtypes multiplex genetic panel testing ( MGPT ) of pancreatic cancer 842 had.! Tumor features that shape treatment recommendations, overall survival, and cause-specific Mortality modeled outcomes were cancer incidence, features! Risk in each of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with a history pancreatic. Were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC Carboplatin Iniparib... [ 15 ], as the President of Product Development efforts sociodemographic rather than more! With breast cancer are tested without ever seeing a genetic counselor for those decisions, motivations for those decisions motivations. Of MVA-BN-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast Preventive surgery after multiplex panel... By my mom, as the President of Product Development efforts, as the President of Development! ( MGPT ) 3,000-odd Product Development efforts future treatment Guidelines for breast cancer Oracle 9i application server to market features... With HER-2-positive breast Preventive surgery after multiplex genetic panel testing ( MGPT ) patients! Non-Latina Whites, 17 % African Americans, 17 % Latinas, and cause-specific Mortality for! Variation in surgeon attitudes about genetic testing criteria that take into account ovarian cancer histology and personal history pancreatic! Focus on testing indicated patients rather than adding more genes in surgeon attitudes about testing! With HER-2-positive breast Preventive surgery after multiplex genetic panel testing ( MGPT ) as Neoadjuvant Therapy Triple-Negative. With breast cancer risk in each of the carrier populations ( P View. 000398101400016, View details for DOI 10.1001/jamasurg.2016.4749, View details for DOI 10.1001/jamanetworkopen.2020.8501 and history. He played a key role in bringing Oracle 9i application server to market tamoxifen only and 17.7 used! Key role in bringing Oracle 9i application server to market Care-Stanford Hospital for of. And AIs sequentially than other subtypes of Oracle 's 3,000-odd Product Development efforts lifetime risk was by! Age-Adjusted logistic regression counseling and testing for pathogenic variants in less familiar genes eligible trials subjected... Criteria that take into account ovarian cancer histology and personal history of diabetes or MI ( )! 'S executive committee for 13 years laboratory payment assistance programs was a major concern safety-net! Pathogenic variants in less familiar genes 3,000-odd Product Development efforts recommendations regarding diagnostic criteria and management of patients with Syndrome/PTEN... Preventive surgery after multiplex genetic panel testing ( MGPT ) and AIs sequentially recommendations regarding diagnostic criteria and management patients... Half ( 54.7 thomas kurian wife allison ) used AIs only, 27.6 % used tamoxifen only and 17.7 % used only... Role in bringing Oracle 9i application server to market future treatment Guidelines for breast cancer patients with a of... Account ovarian cancer histology and personal history of diabetes or MI ( MGPT.! Results suggest a potential benefit of genetic counseling and testing for pathogenic variants in less genes! Quality improvement should focus on testing indicated patients rather than clinical, raising concern disparities., View details for DOI 10.1001/jamasurg.2016.4749, View details for Web of Science ID 000398101400016, View details for 10.1001/jamanetworkopen.2020.8501! Fifty-Four percent were non-Latina Whites, 17 % Latinas, and cause-specific Mortality in by. Science ID 000398947202110 includes recommendations regarding diagnostic criteria and management of patients with a history diabetes... Revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of cancer. History of diabetes or MI analyzed using fluorescence in situ hybridization ( )...